ClinicalTrials.gg
CompletedNCT05134649Updated Dec 5, 2024Results posted

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

A Phase 3 interventional study of OnabotulinumtoxinA in Platysma Prominence, sponsored by AbbVie. Completed at 29 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
292
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence. Participants who completed the lead-in Phase 3 Study M21-309 and met eligibility requirements could enroll in this open-label extension study.

Planned study enrollment was approximately 270 participants. Participants who met treatment criteria could receive up to 3 administrations of BOTOX. Day 1 (study entry) was the same day as Day 120/study exit visit of the lead-in Phase 3 study. The first administration of study drug could occur at the Day 1 visit, and the last administration of study drug could occur at the Day 180 visit (60 days prior to Day 240/study exit). Once a subject was enrolled in this study, monthly follow-up visits occurred.

02

Conditions studied

  • Platysma Prominence

Keywords

  • Platysma Prominence
  • BOTOX
  • OnabotulinumtoxinA
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of all phases of the lead-in Phase 3 study (Screening Period, Treatment Period [randomization/treatment with 4-month follow-up visit] and Study Exit visit)

Exclusion criteria

Exclusion Criteria:

  • Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
  • Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)
  • Anticipated need for surgery or overnight hospitalization during the study
  • Females who are pregnant or breastfeeding and are considering becoming pregnant or donating eggs during the study
  • Known immunization or to any botulinum toxin serotype
  • History of (per investigator's judgment) drug or alcohol abuse within the last 6 months
  • Tattoos, jewelry, or clothing that cannot be removed, and that obscure the target area of interest
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
292 participants (actual)

Study arms

  • Experimental
    BOTOX

    BOTOX (OnabotulinumtoxinA) will be injected into the platysma muscle for up to 3 Cycles during study M21-323

    Drug: OnabotulinumtoxinA

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment.

    Time frame: 371 days (from enrollment in the lead-in study M21-309 through end of study M21-323)

07

Results

Posted Dec 5, 2024

Participant flow

A total of 292 participants were enrolled at 28 sites in the United States and Canada. All participants received at least 1 dose of open-label BOTOX and were included in the intent-to-treat (ITT) and safety populations.

Participant flow — Overall Study
MilestoneBOTOX
Started292
Completed262
Not completed30
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject14
Withdrew: Pregnancy1
Withdrew: Other, not specified3

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment.

Time frame:
371 days (from enrollment in the lead-in study M21-309 through end of study M21-323)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPlacebo (Lead-in)BOTOX (Cycle 1)BOTOX (Cycle 2)BOTOX (Cycle 3)BOTOX (Cycle 4)BOTOX (All Treatment Cycles)Total
Number of Participants With Adverse Events3374462611111127

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from enrollment in M21-323 to the end of study. The median time participants were followed was 239.0 days.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BOTOX0/292 (0%)2/292 (0.7%)42/292 (14.4%)
Most frequent serious events
Most frequent serious events
EventBOTOX
CELLULITISInfections and infestations1/292
HYPONATRAEMIAMetabolism and nutrition disorders1/292
Most frequent other events
Most frequent other events
EventBOTOX
COVID-19Infections and infestations22/292
INJECTION SITE BRUISINGGeneral disorders12/292
NASOPHARYNGITISInfections and infestations12/292

Baseline characteristics

ITT Population

Age, Categorical
Age, Categorical(Participants)BOTOX
<=18 years0
Between 18 and 65 years278
>=65 years14
Age, Continuous
Age, Continuous(Years)BOTOX
Mean49.6 ± 9.76
Sex: Female, Male
Sex: Female, Male(Participants)BOTOX
Female273
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BOTOX
Hispanic or Latino31
Not Hispanic or Latino261
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BOTOX
American Indian or Alaska Native0
Asian15
Native Hawaiian or Other Pacific Islander0
Black or African American12
White265
More than one race0
Unknown or Not Reported0
08

Study locations

29 sites
  • Advanced Research Associates - Glendale /ID# 231997
    Glendale, Arizona 85308, United States
  • Clear Dermatology & Aesthetics Center /ID# 231990
    Scottsdale, Arizona 85255-4134, United States
  • Clinical Testing of Beverly Hills /ID# 231986
    Encino, California 91436-2124, United States
  • Steve Yoelin MD Medical Assoc. Inc /ID# 232004
    Newport Beach, California 92663-3311, United States
  • Cosmetic Laser Dermatology /ID# 232414
    San Diego, California 92121-2119, United States
  • Ava T. Shamban MD - Santa Monica. /ID# 232000
    Santa Monica, California 90404-2208, United States
  • Art of Skin MD /ID# 231995
    Solana Beach, California 92075-2228, United States
  • DMR Research PLLC /ID# 231998
    Westport, Connecticut 06880-5369, United States
  • Susan H. Weinkle MD /ID# 232001
    Bradenton, Florida 34209-5642, United States
  • Research Institute of the Southeast, LLC /ID# 231974
    West Palm Beach, Florida 33401-2712, United States
  • Laser and Skin Surgery Center of Indiana /ID# 231983
    Indianapolis, Indiana 46260-2386, United States
  • Coleman Center For Cosmetic Dermatologic Surgery /ID# 231977
    Metairie, Louisiana 70006, United States
  • Delricht Research /ID# 231985
    New Orleans, Louisiana 70115, United States
  • Aesthetic Center at Woodholme /ID# 231996
    Baltimore, Maryland 21208-6391, United States
  • Maryland Dermatology Laser, Skin, & Vein Institute /ID# 232002
    Hunt Valley, Maryland 21030-3216, United States
  • Image Dermatology, P.C. /ID# 231980
    Montclair, New Jersey 07042, United States
  • Laser & Skin Surgery Center of New York /ID# 231982
    New York, New York 10016-4974, United States
  • Aesthetic Solutions /ID# 231978
    Chapel Hill, North Carolina 27517-9901, United States
  • Wilmington Dermatology Center /ID# 231981
    Wilmington, North Carolina 28403, United States
  • Aventiv Research Dublin /ID# 231994
    Dublin, Ohio 43016, United States
  • KGL Skin Study Center, LLC /ID# 231993
    Newtown Square, Pennsylvania 19073-2228, United States
  • Nashville Center for Laser and Facial Surgery /ID# 231975
    Nashville, Tennessee 37203-1513, United States
  • Dallas Plastic Surgery Institute /ID# 231999
    Dallas, Texas 75231, United States
  • SkinDC /ID# 231989
    Arlington, Virginia 22209, United States
  • Premier Clinical Research /ID# 232003
    Spokane, Washington 99202, United States
  • Humphrey Cosmetic Dermatology /ID# 239649
    Vancouver, British Columbia V5Z 4E1, Canada
  • Dermetics Cosmetic Dermatology /ID# 239650
    Burlington, Ontario L7N 3N2, Canada
  • Dr Melinda Gooderham Medicine Profession /ID# 239647
    Cobourg, Ontario K9A 0Z4, Canada
  • The Center For Dermatology /ID# 239651
    Richmond Hill, Ontario L4B 1A5, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Aug 2023, 21 months.

Results were first posted in Dec 2024, 1 year 3 months after primary completion. A results delay was requested in May 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Nov 26, 2021
StartActual
Nov 16, 2021
Primary completionActual
Aug 18, 2023
CompletionActual
Aug 18, 2023
Results delay requested
May 30, 2024
Results first posted
Dec 5, 2024
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05134649
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 26, 2021
Start date
Nov 16, 2021
Primary completion
Aug 18, 2023
Completion
Aug 18, 2023
Results posted
Dec 5, 2024
Last update
Dec 5, 2024

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion